NCT04804696终止2 期
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2021年2月10日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Pathologic complete response rate
研究概览
简要总结
Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is the standard treatment for local advanced esophageal cancer (EC). It had been demonstrated that patients who achieve pathologic complete response (pCR) after neoadjuvant treatment had better prognosis. However, the pCR rate were about only 5-10% in neoadjuvant chemotherapy and 20-40% in neoadjuvant concurrent chemoradiotherapy.
PD-1 antibody based immunotherapy alone as second-line treatment or combined with chemotherapy as first-line treatment had been proved that could prolong overall survival of EC patients. And a recent phase 3 clinical trial CheckMate 577 reported that, as adjuvant treatment, nivolumab could improve disease-free survival in EC and esophageal-gastric junction cancer.
The aim of this study was to evaluate the efficacy and safety of toripalimab, an anti-PD-1 antibody, combined with paclitaxel and cisplatin as neoadjuvant treatment in local advanced esophageal squamous cell carcinoma (ESCC). We hope this combining treatment would increase the pCR rate of neoadjuvant chemotherapy and improve survival of patients, and at the menatime avoid the adverse events of neoadjuvant radiotherapy. This study will provide valuable information for further clinical trials of both Toripalimab and other immune checkpoint inhibition agents in treatment of esophageal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-70 years old, both gender.
- •Histopathologically confirmed esophageal squamous cell carcinoma.
- •No previous chemotherapy, radiotherapy, traditional Chinese medicine and other anti-tumor treatments.
- •Imaging (CT or MR) or ultrasound endoscopy confirmed local advanced resectable lesions ( AJCC 8th edition standard, stage 3N0M0 or T1-4aN+M0).
- •The ECOG performance status score of 0-
- •Normal functionof all major organs, that is:
- •Hemoglobin (Hb) ≥ 100g/L,
- •Neutrophils (ANC) ≥ 1.5×109/L, ③ Platelet count (PLT) ≥100×109/L, ④ Prothrombin time (PT) and partial prothrombin time (PTT) ≤ 1.5×upper limit of normal (ULN). (For the use of a stable dose of anticoagulant therapy such as low molecular weight heparin or warfarin, if the INR is within the expected therapeutic range of anticoagulants, patient could be screened); ⑤ Serum creatinine (Cr) ≤ 1.5 ×ULN, or 24-hour creatinine clearance rate >60mL/min（Cockcroft-Gault）; ⑥ Total blood bilirubin (TB) ≤ 1.5ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN; albumin (ALB) ≥ 30g/L.
- •The cardiac function is basically normal, the left ventricular ejection fraction is ≥50%, and the blood pressure is under controlled within 140/90 mmHg before enrollment.
- •Pulmonary function is basically normal, without moderate to severe obstructive and diffuse dysfunction.
- •Be able to provide tissue samples for biomarkers analysis, such as PD-L1 expression.
- •Women of childbearing age must have taken reliable contraceptive measures or undergo a pregnancy test (serum) within 7 days before enrollment, and the result is negative, and are willing to use appropriate methods of contraception. For men, they must agree to use appropriate methods of contraception or have been surgically sterilized during the trial period and within 8 weeks after the last trial drug administration;
- •Voluntarily sign an informed consent form (or signed by a legal representative) to prove that they understand the purpose of the research and the operations required by the research and are willing to participate in the research.
排除标准
- •Adenocarcinoma, small cell carcinoma, and other non-squamous cell carcinoma types of esophageal cancer.
- •Imaging examinations (CT or MRI) or endoscopic ultrasonography revealed early stage esophageal cancer, including: carcinoma in situ (Tis), lesions only invaded the mucosa layer or the muscularis propria without lymph node metastasis (T1-2N0).
- •Imaging examinations (CT or MRI) revealed unresectable disease including invasion of vertebral body, aorta, and organs (T4b), or with distant metastases such as lungs, liver, bones and other organ metastases (M1) ;
- •Imaging (esophagography, CT or MR) examination within 4 weeks before enrollment revealed esophageal mediastinal fistula or esophagotracheal fistula.
- •Gastrointestinal bleeding such as hematemesis or melena within 4 weeks before the first dose of treatment.
- •Allergic to PD-1 antibodies, paclitaxel, or cisplatin.
- •Receiving previous anti-tumor treatments such as chemotherapy, radiotherapy, molecular targeted therapy, or Chinese medicine treatment within 4 weeks before enrollment.
- •Receiving corticosteroids (>10 mg prednisone or equivalent dose per day) or other immunosuppressive therapy within 2 weeks before enrollment, except for those who use corticosteroids to prevent allergies, nausea, and vomiting.
- •Received live vaccines within 4 weeks before the first dose of treatment.
- •Receiving major surgery or suffered severe trauma within 4 weeks before the first dose of treatment.
- •Complicated with active autoimmune diseases, or history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but Not limited to these diseases or syndromes). Except: vitiligo, cured childhood asthma/allergic adults without any intervention, autoimmune-mediated hypothyroidism treated with a stable dose of thyroid replacement hormone, and type I diabetes with a stable dose of insulin.
- •A history of immunodeficiency, including HIV positive, acquired or congenital immunodeficiency diseases, organ transplantation, or bone marrow transplantation.
- •With clinical symptoms of cardiovascular diseases which were not well controlled, including but not limited to: heart failure above NYHA II; unstable angina; myocardial infarction within 1 year; clinically significant supraventricular or ventricular arrhythmia and is still uncontrolled without clinical intervention or clinical intervention;
- •Severe infections (CTC AE> Grade 2) occurred within 4 weeks before the first dose of treatment, such as severe pneumonia, bacteremia, infectious comorbidities that require hospitalization, etc.; baseline chest imaging examinations suggest the presence of active lungs Inflammation; having symptoms and signs of infection or taken oral or intravenous antibiotic treatment within 2 weeks before the first dose of treatment except for prophylactic use of antibiotics.
- •A history of interstitial lung disease and a history of non-infectious pneumonia.
- •With active pulmonary tuberculosis infection identified by medical history or CT examination, or a history of active pulmonary tuberculosis infection within 1 year before enrollment.
- •Active hepatitis B (quantity of HBV DNA ≥100 IU/mL), or hepatitis C (hepatitis C antibody is positive, and HCV-RNA is higher than the lower limit of the analytical method) infection.
- •Complicated with chronic nephritis, or urine routine test indicates urine protein ≥ ++, or 24-hour urine protein ≥ 1.0 g.
- •Abnormal blood coagulation function (INR or PT or PTT> 1.5 ULN), potential risk of bleeding, or receiving thrombolysis or anticoagulation therapy;
- •With other malignant tumor diagnosed within 5 years before the first dose of treatment. Exclude malignant tumors with low risk of metastasis and death, such as fully treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
- •Women who are pregnant or breastfeeding.
- •According to the researcher's judgment, there are other factors that may lead to forced termination. Such as suffering from other serious diseases (including mental illness) requiring combined treatment, significant abnormal laboratory test values, or family or social factors, etc., may affect the safety of subjects or the collection of experimental data.
研究组 & 干预措施
TPC treatment
Experimental
Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
干预措施: Toripalimab (Drug)
TPC treatment
Experimental
Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
干预措施: Paclitaxel (Drug)
TPC treatment
Experimental
Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
干预措施: Cisplatin (Drug)
结局指标
主要结局
Pathologic complete response rate
时间窗: Three weeks after surgery of last enrolled subject. Estimate up to 2 years
The rate of pathologic complete response rate after neoadjuvant therapy.
次要结局
- Disease-free survival(From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first. Estimate up to three years.)
- Objective Response Rate(One month after 2 cycles' treatment of last enrolled subject. Estimate up to 2 years)
- Adverse events(From enrollment to 60 days after the end protocol treatment)
- Major pathologic response rate(Three weeks after surgery of last enrolled subject. Estimate up to 2 years.)
- Overall survival(From enrollment to death of patients. Estimate up to 5 years.)
- R0 resection rate(Three weeks after surgery of last enrolled subject. Estimate up to 2 years)
研究者
Xiaodong Zhang
Dean of VIP2 Gastrointestinal Cancer Division of Medical Department, Beijing Cancer Hospital
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerEsophageal Squamous Cell Carcinoma by AJCC V8 StageResectable Esophageal CancerNCT04006041Jianhua Fu44
尚未招募
2 期
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05306847Peking Union Medical College Hospital93
进行中（未招募）
1 期
Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyNasopharyngeal CancerNCT04850235Sun Yat-sen University36
Unknown
2 期
Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)Non-small Cell Lung CancerNCT01158144Zhejiang Cancer Hospital134
已完成
1 期
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma PatientsInduction ChemotherapyProgrammed Cell Death 1 InhibitorInductive TherapyOral CancerNCT04473716Shanghai Jiao Tong University School of Medicine20